Colin Bristow

Stock Analyst at UBS

(0)
# 5012
Out of 5,386 analysts
100
Total ratings
Success rate
Average return
23 Stocks
Name Action PT Current % Upside Ratings Updated
RCKT Rocket Pharmaceutica...
Maintains: Buy
12 5
2.52 98.41% 3 Jun 17, 2025
ALXO ALX Oncology Holding...
Maintains: Buy
2 1
n/a n/a 6 May 21, 2025
IMVT Immunovant
Downgrades: Neutral
38 17
16.12 5.46% 6 Apr 22, 2025
AMGN Amgen
Maintains: Neutral
315 319
277.28 15.05% 9 Apr 14, 2025
ABOS Acumen Pharmaceutica...
Maintains: Buy
6 4
1.16 244.83% 4 Mar 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
34 7
3.66 91.26% 2 Feb 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
586 583
441.18 32.15% 14 Feb 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
29 28
24.2 15.7% 12 Feb 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
125 120
78.93 52.03% 6 Jan 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
47 71
49.79 42.6% 3 Dec 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
70 96
110.71 -13.29% 3 Nov 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
234 202
125.95 60.38% 10 Oct 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
56 16
1.76 809.09% 5 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
1090 1099
520.94 110.96% 1 Apr 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
164 167
17.1 876.61% 5 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
428 420
776.25 -45.89% 1 Dec 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
12 2
3.19 -37.3% 2 Dec 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
18
0.69 2508.7% 1 Oct 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
154 146
181.89 -19.73% 2 Aug 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
73 75
46.33 61.88% 1 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
64 26
1.43 1718.18% 1 Apr 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
9
4.9 83.67% 1 Aug 23, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
195
n/a n/a 2 Feb 1, 2021